US 10,294,239 B2Granted

Ertugliflozin co-crystals and process for their preparation

AssigneeSun Pharmaceutical Industries Limited

InventorsRamkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri

Life of this patent

Estimating the term…

Abstract

The present invention relates to processes for the preparation of an ertugliflozin-L-pyroglutamic acid (1:1) and co-crystal ertugliflozin-L-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-L-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus.

Claims11

Dependent claims

Ertugliflozin-L-proline (1:2) co-crystal of Formula Ia

Dependencies are inferred from the claim text.

Facts

Application: 15/576,452Filed 24 May 2016
Priority: IN 1471/DEL/201525 May 2015
Published: US 2018/0155358 A17 Jun 2018
Granted: 21 May 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C07D 493/08
In which the condensed system contains two hetero rings: bridged systems
A61K 31/357
Having oxygen as the only ring hetero atom, e.g. fungichromin: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/401
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: proline; Derivatives…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

US 2018/0155358 A1Pre-grant publication · published 7 Jun 2018
US 10,294,239 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results